Welcome to Visited Lingnan Modern Clinics In Surgery, Today is

Lingnan Modern Clinics In Surgery ›› 2024, Vol. 24 ›› Issue (01): 76-86.DOI: 10.3969/j.issn.1009-976X.2024.01.012

• Review • Previous Articles    

Predictive value of tumor infiltrating lymphocytes in breast cancer patients under different molecular subtypes

MENG Lan-lan1,2, JIN Hao1,2, YAO Yan-dan1,2   

  1. 1. Key Laboratory of Epigenetics, Gene Regulation of Malignant Tumors of Guangdong Province, Breast Tumor Hospital, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou510120, China;
    2. Shamshuipo Central Hospital, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Shanwei516621, China
  • Contact: YAO Yan-dan, yaoyand@mail.sysu.edu.cn

肿瘤浸润性淋巴细胞在不同分子分型乳腺癌患者预后中的预测价值

孟兰兰1,2, 靳浩1,2, 姚燕丹1,2,*   

  1. 1.中山大学孙逸仙纪念医院乳腺肿瘤医院,广东省恶性肿瘤表观遗传与基因调控重点实验室,广州 510120;
    2.中山大学孙逸仙纪念医院深汕中心医院,汕尾 516621
  • 通讯作者: *姚燕丹,Email: yaoyand@mail.sysu.edu.cn
  • 基金资助:
    国家自然科学基金(82071859,82371856); 广东省科技基金(2019A050510016,2021B1515230001); 广东省创新创业团队项目(2019BT02Y198)

Abstract: Tumor-infiltrating lymphocytes (TILs) are an important part of the tumor microenvironment and play an important role in the anti-tumor immune response of breast cancer. According to gene expression analysis or immunohistochemical markers of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) expression, breast cancer can be divided into triple negative breast cancer (TNBC), HER2 positive breast cancer, Luminal breast cancer. The predictive value of TILs is different in different subtypes of breast cancer. The prognosis of TILs in breast cancer varies not only because of the different levels of TILs, but also because of the presence of both anti-tumor and pro-tumor subgroups in TILs, and the various subgroups of TILs differs in different patients.

Key words: tumor-infiltrating lymphocytes, triple negative breast cancer, HER2 positive breast cancer, luminal breast cancer

摘要: 肿瘤浸润性淋巴细胞(TILs)是肿瘤微环境的重要组成部分,在乳腺癌的抗肿瘤免疫应答中发挥着重要的作用。乳腺癌根据基因表达分析或免疫组织化学标记物雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体2(HER2)的表达可以分为三阴性乳腺癌(TNBC)、HER2阳性乳腺癌、Luminal型乳腺癌,TILs对不同亚型的乳腺癌预后的预测价值不同。TILs对乳腺癌预后的不同不仅是因为TILs的浸润水平不同,也是因为TILs中同时存在有抗肿瘤和促肿瘤的亚群,不同患者中TILs的各种亚群也存在差异。

关键词: 肿瘤浸润性淋巴细胞, 三阴性乳腺癌, HER2阳性乳腺癌, Luminal型乳腺癌

CLC Number: